Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel versus paclitaxel + cetuximab in recurrent/metastatic head and neck squamous cell carcinoma after progression on EXTREME
2010-019061-28Phase 2Terminated
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- Start
- Jun 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing Paclitaxel monotherapy with Paclitaxel + cetuximab (2 arms). Primary endpoint: Progression-free survival. Started Jun 2010; status: terminated.
02
Drugs
cetuximabpaclitaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2010-019061-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019061-28.